Company news
Insmed Incorporated (NASDAQ:INSM) news
Insmed Incorporated news releases on 6ix. Latest, Apr 22, 2021: Insmed to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021
Press releases — page 4
Insmed to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021
April 21, 2021
ARIKAYCE® (amikacin liposome inhalation suspension) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to Prior Treatment with MDR
March 22, 2021
Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
February 24, 2021
Insmed to Present at Two March Conferences
February 23, 2021
Insmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP)
February 18, 2021
Insmed to Host Conference Call to Discuss Topline Data from Treprostinil Palmitil Inhalation Powder Phase 1 Study
February 15, 2021
Insmed to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021
February 11, 2021
Insmed to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 4, 2021
Insmed Initiates Frontline Clinical Trial Program for ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with MAC Lung Disease
January 3, 2021
Insmed Announces Initiation of Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
December 1, 2020
Insmed to Present at the Evercore ISI 3rd Annual HealthCONx Conference
November 23, 2020
Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)
November 12, 2020
Insmed to Present at Two November Conferences
November 1, 2020
Insmed Reports Third Quarter 2020 Financial Results and Provides Business Update
October 28, 2020
European Commission Grants Marketing Authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Treatment Options
October 27, 2020
Insmed to Host Third Quarter 2020 Financial Results Conference Call on Thursday, October 29, 2020
October 19, 2020
Insmed Highlights Progress Across Portfolio and Outlines Growth Strategy at R&D Day
September 29, 2020
Insmed to Host R&D Day on September 30, 2020
September 15, 2020
Insmed to Present at Three September Conferences
September 8, 2020
New England Journal of Medicine Publishes Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis
September 6, 2020
Insmed Reports Second Quarter 2020 Financial Results and Provides Business Update
August 5, 2020
Insmed to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 6, 2020
July 26, 2020
Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options
July 23, 2020
New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung Disease
July 6, 2020
Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at ATS Virtual Clinical Trials Session
June 23, 2020
Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)
June 7, 2020
Insmed to Present at Two June Conferences
May 25, 2020
Insmed to Showcase New Brensocatib Data at American Thoracic Society Virtual Clinical Trials Session
May 19, 2020
Insmed Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
May 6, 2020
Insmed Announces Pricing of Public Offering of Common Stock
May 4, 2020
Insmed Announces Proposed Public Offering of Common Stock
May 3, 2020
Insmed Reports First Quarter 2020 Financial Results and Provides Business Update
April 29, 2020
Brensocatib (Formerly INS1007) to be Studied in Patients with Severe COVID-19 in Investigator-Initiated Trial
April 22, 2020
Insmed to Host First Quarter 2020 Financial Results Conference Call on Thursday, April 30, 2020
April 19, 2020
Insmed Appoints Carol A. Schafer to its Board of Directors
April 1, 2020
Insmed Provides Business Update
March 15, 2020
Insmed Announces Publication Discussing the Clinical Management of Common Respiratory Events Associated with ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in the Journal Open Forum Infectious Disease
March 3, 2020
Insmed to Present at the Cowen and Company 40th Annual Health Care Conference
February 25, 2020
Insmed Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
February 24, 2020
Insmed to Present at the 9th Annual SVB Leerink Global Healthcare Conference
February 18, 2020
Insmed to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call on Tuesday, February 25, 2020
February 9, 2020
Insmed Announces Positive Top-Line Results from Phase 2 WILLOW Study of INS1007 in Patients with Non-Cystic Fibrosis Bronchiectasis
February 2, 2020
Insmed Appoints Sara Bonstein as Chief Financial Officer
January 29, 2020
Insmed to Present at Two December Conferences
November 25, 2019
Insmed Appoints Dr. Clarissa Desjardins to its Board of Directors and Names Roger Adsett Chief Operating Officer
November 13, 2019
Insmed Reports Third Quarter 2019 Financial Results and Provides Business Update
October 29, 2019
Insmed to Host Third Quarter 2019 Financial Results Conference Call on Wednesday, October 30, 2019
October 22, 2019
Insmed to Present at Two September Conferences
September 2, 2019
Insmed Reports Second Quarter 2019 Financial Results and Provides Business Update
July 31, 2019
Insmed to Host Second Quarter 2019 Financial Results Conference Call on Thursday, August 1, 2019
July 24, 2019